Every 10-Q that Outset Medical, Inc. (OM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OM filings page.
Outset Medical (OM) reported Q3 2025 results showing modest top-line growth and narrower losses. Revenue was $29.4 million, up slightly from $28.7 million a year ago, with product revenue of $20.6 million and service and other revenue of $8.9 million. Gross profit rose to $11.6 million as operating expenses declined, reducing the operating loss to $15.8 million. Net loss was $17.8 million, or $1.00 per share.
For the first nine months of 2025, revenue reached $90.6 million versus $84.2 million in 2024, and net loss improved to $62.2 million from $102.3 million. Cash, cash equivalents, restricted cash and short‑term investments totaled $182.0 million as of September 30, 2025. The company executed a 15‑for‑1 reverse stock split in March 2025 and completed financing steps earlier in the year, including issuing Series A convertible preferred stock that largely converted into 14,046,000 common shares at $12.00 per share and entering a $125 million term loan facility (with $100 million funded). As of November 6, 2025, shares outstanding were 18,153,090.